The US Bankruptcy Court granted an order for the extension of the exclusivity periods for Sorrento Therapeutics, Inc. on October 5, 2023. As per the order, the debtor?s exclusivity period to file its plan and to solicit votes on its plan, have been extended by 20 days i.e. up to October 16, 2023 and December 15, 2023, respectively.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0122 USD | +41.86% | -15.86% | -90.12% |
Apr. 10 | Sorrento Therapeutics, Inc. Emerged from Bankruptcy | CI |
Mar. 15 | Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs | MT |
1st Jan change | Capi. | |
---|---|---|
-90.12% | 4.68M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- SRNE Stock
- News Sorrento Therapeutics, Inc.
- Third Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.